A two-trial phase 3 clinical program for APL-2 for geographic atrophy has begun with the first patient enrolled in the DERBY trial and the first patient dosed in the OAKS trial, Apellis Pharmaceuticals announced in a press release.
The two-trial prospective, international, multicenter, randomized, double-masked, sham-injection controlled program will include 600 patients with geographic atrophy and assess the efficacy and safety of multiple intravitreal injections of APL-2, the release said.
“Dosing the first patient in our phase 3 program in geographic atrophy is an exciting milestone
Uncategorized